Evaluation of terminal complement cascade inhibitors using in vitro and in vivo models of age-related macular degeneration and in Alzheimer’s Disease

Age-related macular degeneration (AMD) is a leading cause of blindness that is estimated to affect over 6 million people globally. There are currently no approved treatments for dry AMD, the most common form of the disease. Various lines of inquiry suggest that dysregulation of a part of the innate immune system called complement plays a […]

Read More